Camurus, Lilly collaboration and license agreement for long-acting FluidCrystal® incretins

Camurus (CAMX) and Eli Lilly have formed a strategic collaboration and license agreement for developing long-acting incretin therapies using Camurus' FluidCrystal technology. The partnership grants Lilly exclusive worldwide rights to develop and commercialize up to four proprietary drug compounds for cardiometabolic health. Under the agreement terms, Camurus is eligible to receive up to $870 million in total payments, comprising $290 million in upfront, development, and regulatory milestones, plus $580 million in sales-based milestones. Additionally, Camurus will receive tiered mid-single digit royalties on global net product sales. The collaboration focuses on dual GIP and GLP-1 receptor agonists, triple GIP, glucagon and GLP-1 receptor agonists, with an option to include amylin receptor agonists.

https://www.stocktitan.net/news/CAMX/camurus-and-lilly-enter-collaboration-and-license-agreement-for-long-2saf79vso2qx.html